Concurrent Chemoradiation With 5-Fluorouracil and Mitomycin in Squamous Cell Carcinoma of the Rectum

Rectal carcinoma-squamous type is infrequently seen. Etiopathogenesis, prognosis, and therapeutic management of rectal squamous cell carcinoma (SCC) are not clearly defined. Rectal SCC is now approached with definitive upfront chemoradiotherapy (CRT), with 5-fluorouracil (5-FU) and mitomycin with a...

Descripción completa

Detalles Bibliográficos
Autor principal: Sethi, Ashish K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8476189/
https://www.ncbi.nlm.nih.gov/pubmed/34603888
http://dx.doi.org/10.7759/cureus.17518
Descripción
Sumario:Rectal carcinoma-squamous type is infrequently seen. Etiopathogenesis, prognosis, and therapeutic management of rectal squamous cell carcinoma (SCC) are not clearly defined. Rectal SCC is now approached with definitive upfront chemoradiotherapy (CRT), with 5-fluorouracil (5-FU) and mitomycin with a goal to avoid surgery. However, its management is planned based on histology features regardless of the localization of SCC rectal cancer. We present a case of a 47-year-old Caucasian female with rectal SCC who is under remission for two years after being treated with upfront chemoradiation with mitomycin and 5-fluorouracil (5-FU).

Ejemplares similares